doi:10.16150/j.1671-2870.2021.01.002

Abstract

CLC Number:

R593.2

Figures/Tables 1

	建议综合管理	RG
联合疗法	抗MDA5抗体阳性DM(或CADM)合并RPILD患者应首选联合疗法	D
1	糖皮质激素（激素）加钙调磷酸酶抑制剂（环孢素A或他克莫司）的联合疗法,或在此基础上加用静脉滴注环磷酰胺^a) 的三联疗法,均被认为是较好的初始选择	D
	a环孢素A和他克莫司疗效均好,临床选择基于其药物安全性及患者特征	√
	b建议监测钙调磷酸酶抑制剂的血药浓度以调整剂量,减少毒副作用	√
2	当钙调磷酸酶抑制剂不可行时,应考虑糖皮质激素联合其他免疫抑制剂[如环磷酰胺^b)和（或）吗替麦考酚酯],或将利妥昔单抗^b)加到任一先前的治疗方案中	D
	a这些药物的选择基于患者的个体特征及医生的临床经验	√
难治性DM(或CADM)合并RPILD患者的治疗
1	对激素联合免疫抑制剂治疗无效的患者,应考虑以下替代方案
	a在当前治疗方案中加用以下任一免疫抑制剂：环磷酰胺、吗替麦考酚酯、利妥昔单抗、巴利昔单抗或托法替布	D
	b换用另一种免疫抑制剂	√
2	对激素联合免疫抑制剂治疗无反应的患者,可单独或依次采用以下替代疗法
	a多黏菌素B血液灌流	D
	b 血浆置换	D
	c 静脉注射免疫球蛋白	√
3	对出现危及生命的严重和（或）难治性呼吸功能不全的患者,应考虑使用ECMO来维持患者的生命,等待患者对强化联合免疫抑制疗法的临床反应或作为肺移植前的桥梁阶段	√
4	对难治性患者应考虑肺移植,在诊断RPILD后应尽早转诊,进行移植资格评估	√
其他治疗选择
1	不建议将硫唑嘌呤、氨甲蝶呤和来氟米特用于治疗此类患者	√
2	不建议在治疗中使用英夫利昔单抗	√
3	尽管在肺纤维化的数据中,吡非尼酮已经被添加到CADM相关的亚急性ILD的常规免疫抑制治疗中,但专家组可能并不建议	√

References 34

[1]	Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis[J]. Curr Opin Rheumatol, 2000, 12(6):501-508. pmid: 11092199
[2]	Cao H, Parikh TN, Zheng J. Amyopathic dermatomyositis or dermatomyositis-like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis[J]. Clin Rheumatol, 2009, 28(8):979-984. doi: 10.1007/s10067-009-1152-9 URL
[3]	Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome[J]. PLoS One, 2013, 8(4):e60442. doi: 10.1371/journal.pone.0060442 URL
[4]	Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis[J]. Arthritis Rheum, 2005, 52(5):1571-1576. doi: 10.1002/art.21023 URL
[5]	Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease[J]. Arthritis Rheum, 2009, 60(7):2193-2200. doi: 10.1002/art.24621 URL
[6]	Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody[J]. Rheumatology (Oxford), 2010, 49(3):433-440. doi: 10.1093/rheumatology/kep375 pmid: 20015976
[7]	Cao H, Pan M, Kang Y, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody[J]. Arthritis Care Res (Hoboken), 2012, 64(10):1602-1610. doi: 10.1002/acr.21728 URL
[8]	Wu Q, Wedderburn LR, McCann LJ. Juvenile dermatomyositis: latest advances[J]. Best Pract Res Clin Rheumatol, 2017, 31(4):535-557. doi: 10.1016/j.berh.2017.12.003 URL
[9]	Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study[J]. Arthritis Res Ther, 2014, 16(4):R138. doi: 10.1186/ar4600 URL
[10]	Kobayashi I, Okura Y, Yamada M, et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis[J]. J Pediatr, 2011, 158(4):675-677. doi: 10.1016/j.jpeds.2010.11.033 URL
[11]	DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis[J]. J Am Acad Dermatol, 2020, 82(2):267-281. doi: 10.1016/j.jaad.2019.06.1309 URL
[12]	Moghadam-Kia S, Oddis CV, Sato S, et al. Antimelanoma Differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis[J]. J Rheumatol, 2017, 44(3):319-325. doi: 10.3899/jrheum.160682 pmid: 28089977
[13]	Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis[J]. Arthritis Care Res(Hoboken), 2013, 65(8):1316-1324.
[14]	Takeuchi O, Akira S. MDA5/RIG-I and virus recognition[J]. Curr Opin Immunol, 2008, 20(1):17-22. doi: 10.1016/j.coi.2008.01.002 pmid: 18272355
[15]	Yoneyama M, Kikuchi M, Matsumoto K, et al. Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP 2 in antiviral innate immunity[J]. J Immunol, 2005, 175(5):2851-2858. doi: 10.4049/jimmunol.175.5.2851 URL
[16]	Nishina N, Sato S, Masui K, et al. Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease[J]. RMD Open, 2020, 6(2):e001202. doi: 10.1136/rmdopen-2020-001202 URL
[17]	Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5(CADM-140): a retrospective study[J]. J Am Acad Dermatol, 2011, 65(1):25-34. doi: 10.1016/j.jaad.2010.09.016 pmid: 21531040
[18]	Narang NS, Casciola-Rosen L, Li S, et al. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease[J]. Arthritis Care Res (Hoboken), 2015, 67(5):667-672. doi: 10.1002/acr.22498 pmid: 25331610
[19]	Cao H, Xia Q, Pan M, et al. Gottron papules and Gottron sign with ulceration: a distinctive cutaneous feature in a subset of patients with classic dermatomyositis and clinically amyopathic dermatomyositis[J]. J Rheumatol, 2016, 43(9):1735-1742. doi: 10.3899/jrheum.160024 URL
[20]	Ono N, Kai K, Maruyama A, et al. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients[J]. Rheumatology (Oxford), 2019, 58(5):786-791. doi: 10.1093/rheumatology/key386 URL
[21]	Disdier P, Harlé JR, Chrestian MA, et al. Extensive pharyngeal necrosis: an unusual complication of dermatomyositis[J]. Rev Med Interne, 1992, 13(3):218-220. pmid: 1410905
[22]	Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5(MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features[J]. J Am Acad Dermatol, 2018, 78(4):776-785. doi: S0190-9622(17)32764-0 pmid: 29229575
[23]	Allenbach Y, Leroux G, Suárez-Calvet X, et al. Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression[J]. Am J Pathol, 2016, 186(3):691-700. doi: 10.1016/j.ajpath.2015.11.010 pmid: 26806087
[24]	Vuillard C, Pineton de Chambrun M, de Prost N, et al. Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: a French multicenter retrospective study[J]. Ann Intensive Care, 2018, 8(1):87. doi: 10.1186/s13613-018-0433-3 URL
[25]	Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis[J]. Rheumatology (Oxford), 2012, 51(9):1563-1570. doi: 10.1093/rheumatology/kes102 URL
[26]	Diao LC, Chen M, Lu YD, et al. Detection of serum ferritin in patients with idiopathic inflammatory myopathies and its clinical significance[J]. Clin J Dermatol, 2016, 49(6):391-395.
[27]	Gono T, Kawaguchi Y, Hara M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis[J]. Rheumatology(Oxford), 2010, 49(7):1354-1360. doi: 10.1093/rheumatology/keq073 URL
[28]	Chen M, Quan C, Diao L, et al. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis[J]. Br J Dermatol, 2018, 179(6):1334-1341. doi: 10.1111/bjd.17079 pmid: 30101523
[29]	蔡怡华, 郑捷. 血清肌酶在评价皮肌炎与多肌炎合并肺间质病变中的作用[J]. 诊断学理论与实践, 2004, 3(4):260-263.
[30]	Vojinovic T, Cavazzana I, Ceruti P, et al. Predictive features and clinical presentation of interstitial lung disease in inflammatory myositis[J]. Clin Rev Allergy Immunol, 2021, 60(1):87-94. doi: 10.1007/s12016-020-08814-5 URL
[31]	Allenbach Y, Uzunhan Y, Toquet S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases[J]. Neurology, 2020, 95(1):e70-e78. doi: 10.1212/WNL.0000000000009727 URL
[32]	Yamaguchi K, Yamaguchi A, Onuki Y, et al. Clinical features of dermatomyositis associated with anti-MDA5 antibodies by age[J]. Mod Rheumatol, 2021, 31(1):177-185. doi: 10.1080/14397595.2020.1740400 URL
[33]	Romero-Bueno F, Diaz Del Campo P, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease[J]. Semin Arthritis Rheum, 2020, 50(4):776-790. doi: 10.1016/j.semarthrit.2020.03.007 URL
[34]	Li LB, Liu CX, Zhang YF. Comparison analysis of anti-MDA5 antibody and anti-TIF1 antibody between ELISA and line blot assay[J]. Int J Lab Med, 2019, 40(9):1028-1031.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 34

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	DIAO Xuehong, SHEN Yan, CHEN Lin, ZHAN Jia, FANG Liang, CAI Jianfei, CHEN Yue. Application of superb microvascular imaging technology in diagnosing rheumatoid arthritis in the clinical remission stage [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(05): 575-580.
[2]	. [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 299-303.
[3]	. [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 304-311.
[4]	ZHANG Hao, CHI Huihui, SU Yutong, YANG Chengde. Study on advances in the association between autoantibodies and clinical phenotypes in idiopathic inflammatory myopathy [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(03): 408-414.
[5]	LU Hongyu, GU Jun, WANG Jing, CAO Yafeng, SONG Luxi, FAN Jun, CHEN Mei. Sjögren′s syndrome secondary to cryptococcal meningoencephalitis: a case report and literature review [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(05): 456-461.
[6]	. [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(01): 98-103.
[7]	. [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 113-116.
[8]	WANG Yanqing, HUANG Wanxue, LIANG Yuanyuan, WU Zhenzhen, WANG Xuan, TANG Jianping. Clinical and laboratory analysis of primary Sjögren′s syndrome complicated with neurological lesions [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 51-55.
[9]	. [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 109-112.
[10]	. [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(05): 616-619.
[11]	. [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(05): 606-610.
[12]	YUAN Yiwei, GU Juanfang, FEI Zhangli, YANG Mingfeng, WANG Yiwen, WANG Hongzhi. Level of programmed cell death factor 5 in patients with active rheumatoid arthritis [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(04): 453-456.
[13]	. [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 244-248.
[14]	. [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 347-351.
[15]	. [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 249-253.